MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Wall Street Zen

MiNK Therapeutics (NASDAQ:INKT) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

Several other research firms have also issued reports on INKT. Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, MiNK Therapeutics has a consensus rating of “Hold” and a consensus target price of $35.00.

MiNK Therapeutics Trading Down 3.1%

INKT stock opened at $12.02 on Friday. The firm has a 50 day moving average of $11.97 and a 200-day moving average of $14.13. The firm has a market capitalization of $56.35 million, a P/E ratio of -3.97 and a beta of 0.34. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $76.00.

MiNK Therapeutics (NASDAQ:INKT) last posted its earnings results on Friday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.21. Sell-side analysts predict that MiNK Therapeutics will post -2.75 EPS for the current year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.